DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Growth Opportunities in the APAC IVD Market, Forecast to 2021" report to their offering.
The APAC IVD industry, worth $ 14.44 billion in 2016, is expected to reach $19.64 billion in 2021 growing at a CAGR of 6.3%.
The study aims to analyze and forecast the Asia Pacific (APAC) in-vitro diagnostics (IVD) market outlook and technology trends for 2016.
In molecular diagnostics, infectious disease has the highest market share of 72.0%, followed by oncology (14.3%), genetic disorders (10.0%), and pharmacogenomics (3.7%). Digital innovations in the IVD industry, such as digital pathology, precision medicine, and health analytics are radically changing the care continuum in APAC. The IVD market is moving towards total laboratory automation from task-targeted automation. Although stand-alone automation systems are cost effective in clinical labs, multiple stakeholders in the healthcare ecosystems including physicians, payers, and administrators demand "connected-pathology solutions."
Research Scope:
- Immunochemistry
- Self-monitoring Blood Glucose (SMBG) Meter
- Hematology
- Point-of-care Testing (POCT)
- Tissue Diagnostics
- Hemostasis
- Clinical Microbiology
- Molecular Diagnostics
Key Topics Covered:
1. Executive Dashboard
2. Growth Environment-Market Overview
3. Market Forecasts
4. Competitive Playbook
5. Growth Pipeline, Strategy, and Implementation
6. Regional Dynamics
7. Segment Analysis
Companies Mentioned
- Abbott
- Agilent
- Becton
- Biomerieux
- Danaher
- Diasorin
- Hologic
- Horbia
- Illumina
- Mindray
- Roche
- Siemens
- Sysmex
- ThermoFisher
For more information about this report visit https://www.researchandmarkets.com/research/dg74ph/growth
